Rising Demand Drives PYFA to Record Net Sales of Rp2.76 Trillion in 2025
PT Pyridam Farma Tbk (IDX: PYFA) recorded accelerated growth in fiscal year 2025, with net sales reaching Rp2.76 trillion, a 43.7% annual increase from Rp1.92 trillion in 2024.
According to the consolidated financial report for fiscal year 2025, the company also showed improvements at the operational level, with EBITDA of Rp203.7 billion and gross profit of Rp583 billion. This reflects business scale expansion and contributions from business lines with better margins.
PYFA’s net sales growth in 2025 was supported by strong expansion in the Contract Development and Manufacturing Organization (CDMO) line, which is increasingly becoming one of the company’s strategic pillars. Continuously increasing demand, both from domestic and global pharmaceutical companies, strengthens PYFA’s position as a trusted and integrated manufacturing partner amid trends in contract manufacturing services in the pharmaceutical industry.
Over the past five years, PYFA has consistently expanded production capacity and strengthened manufacturing infrastructure. This capacity increase is crucial to capturing opportunities in the growing CDMO market, in line with rising needs for efficiency and specialisation in the global pharmaceutical industry.
Several innovative products supporting growth include Cytoflavin, Reamberin, Syalox, and the sterile injection line.
“2025 was a year full of challenges, but our achievements prove PYFA’s fundamental resilience in facing challenging market dynamics. Entering the next phase, the company’s main focus shifts to optimising profitability. We will implement much tighter and more measured operational efficiency steps across all business lines, ensuring the company operates in a leaner and more disciplined manner to support healthy long-term growth,” stated Sinta Ningsih, PYFA Director.
Amid this growth, the company still recorded a net loss, influenced by high operational burdens and ongoing strategic investments. The company stated that this phase is part of efforts to build long-term capabilities and expand PYFA’s position in a broader health ecosystem.
One of the strategic investments made by the company in 2025 was the consolidation of the Probiotec facility in Kemps Creek, New South Wales, Australia, and the completion of the Line 3 facility in Cikarang by the end of the year. The Kemps Creek facility became fully operational by the end of 2025, while the Line 3 facility in Cikarang, which has twice the production capacity of Line 2, is ready for commercial activities in 2026.
The company’s growth strategies for 2026 will focus on three main pillars: expansion of sterile production facilities in Cikarang (Lines 4 and 5), strengthening CDMO services, and focus on high-value and licensed therapeutic product portfolios. These steps are also supported by selective corporate actions that position PYFA as a company with a complete health ecosystem from upstream to downstream.
With a combination of manufacturing capabilities, access to global partnerships, and measured expansion strategies, the company sees opportunities to take a more significant role in the health industry’s value chain, both in domestic and international markets.
The global sterile injectable drug market is estimated to reach around US$4.9 billion in 2026 and potentially increase to nearly US$9.9 billion by 2035.